Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review-Reference-Cited by-同舟云学术

Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review

Published:2015-03 Issue:3 Volume:26 Page:485-496
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Johnson K.R.,Liauw W.,Lassere M.N.D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/3/485/19479972/mdu267.pdf

Reference82 articles.

1. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group;Gleave;N Engl J Med,1998

2. Sorafenib for the treatment of advanced renal cell carcinoma;Kane;Clin Cancer Res,2006

3. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma;Goodman;Clin Cancer Res,2007

4. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the committee for medicinal products for human use;Nieto;Clin Cancer Res,2011

5. FDA. Axitinibhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm (21 January 2013, date last accessed)

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis;European Urology Open Science;2023-01

2. The validity of progression‐free survival 2 as a surrogate trial end point for overall survival;Cancer;2022-01-05

3. Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis;International Journal of Technology Assessment in Health Care;2021-12-22

4. The value of anticancer drugs — a regulatory view;Nature Reviews Clinical Oncology;2021-12-06

5. Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico;Value in Health Regional Issues;2021-12